Early Stage CRO Celerion Adopts Participant Verification System
Celerion is pleased to announce it has implemented VCT Verify™ from Verified Clinical Trials, to instantaneously ensure accurate participant identification and qualification for clinical research. Celerion is the first Early Stage Contract Research Organization (CRO) to partner with Verified Clinical Trials to set the standard for the industry to adopt.
Celerion will more effectively screen and select higher quality study participants by using this tool to instantly identify ineligible candidates for enrollment. The system searches a global clinical database registry to identify participants that are currently enrolled in other clinical studies. Clients benefit from improved participant selection and higher data integrity.
Celerion chose to implement the VCT Verify™ product across all our global clinical facilities to solve the long recognized problem of inaccurate applications that compromise study success. The system has been reviewed and applauded by numerous Institutional Review Boards (IRBs) and Verified Clinical Trials is safe harbor certified.
“Celerion continues to apply rigorous standards to protect the safety of participants and enhance data integrity while supporting our commitment to our clients. This implementation sets a standard in the industry to continue to improve clinical research and more effectively bring new drugs to the market,” said Phil Bach, Vice President of Global Clinical Research at Celerion. “We are excited to partner with Verified Clinical Trials, the leader in this specialized field, to take a firm stance on ensuring the highest quality data and participants for our clients.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
